Teva's Ajovy, chasing Amgen and Lilly drugs, gains steam after autoinjector rollout

Upon its FDA approval in 2018, Teva’s migraine prevention medicine Ajovy faced tough prospects as it trailed a rival into the market with a less desirable delivery method. Nearly two years later, with an approval for an autoinjector device in hand, Teva's launch is beginning to kick into gear.